Form 8-K - Current report:
SEC Accession No. 0001437749-23-015120
Filing Date
2023-05-18
Accepted
2023-05-18 16:30:39
Documents
14
Period of Report
2023-05-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dmtp20230518_8k.htm   iXBRL 8-K 55381
2 EXHIBIT 3.1 ex_523059.htm EX-3.1 423100
  Complete submission text file 0001437749-23-015120.txt   667051

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dmac-20230517.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dmac-20230517_def.xml EX-101.DEF 11901
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dmac-20230517_lab.xml EX-101.LAB 15926
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dmac-20230517_pre.xml EX-101.PRE 12112
8 EXTRACTED XBRL INSTANCE DOCUMENT dmtp20230518_8k_htm.xml XML 2655
Mailing Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305
Business Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 (763) 496-5454
DiaMedica Therapeutics Inc. (Filer) CIK: 0001401040 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36291 | Film No.: 23936526
SIC: 2834 Pharmaceutical Preparations